High p53 and MAP1 light chain 3A co-expression predicts poor prognosis in patients with esophageal squamous cell carcinoma

Wang,Zhen‑Bo; Peng,Xian‑Zhong; Chen,Shao‑Shui; Ning,Fang‑Ling; Du,Chun‑Juan; Wang,Kai; Ma,Wei; Cheng,Yu‑Feng

doi:10.3892/mmr.2013.1451

High p53 and MAP1 light chain 3A co-expression predicts poor prognosis in patients with esophageal squamous cell carcinoma

Authors:
- Zhen‑Bo Wang
- Xian‑Zhong Peng
- Shao‑Shui Chen
- Fang‑Ling Ning
- Chun‑Juan Du
- Kai Wang
- Wei Ma
- Yu‑Feng Cheng
View Affiliations

Affiliations: Oncology Center, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Oncology, The Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong 256603, P.R. China
Published online on: April 30, 2013 https://doi.org/10.3892/mmr.2013.1451
Pages: 41-46

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

p53 and microtubule-associated protein 1 light chain 3A (LC3A) are regulators of apoptosis and autophagy and are expressed at high levels in a number of human tumors. The purpose of the current study was to evaluate the clinicopathological and prognostic significance of p53 and LC3A expression levels in esophageal squamous cell carcinomas (ESCCs). p53 and LC3A expression levels were measured by immunohistochemistry in 114 patients with stage II/III (Tany N+M0 or T3,4 Nany M0) ESCCs treated with surgery followed by adjuvant concurrent chemoradiotherapy. The overexpression of p53 and LC3A was observed in 57 and 54% of ESCC samples, respectively. p53 staining was nuclear and LC3A was localized to the cytoplasm of tumor cells. p53 overexpression was more frequently observed in ESCCs with positive lymph nodes (P=0.017). Patients with ESCCs overexpressing p53 and LC3A were associated with a lower 5‑year overall survival rate than those with low p53 and LC3A expression (18.0 vs. 54.4%; P=0.001). Univariate and multivariate analyses revealed that the overexpression of p53 or LC3A was not associated with poor patient outcome (P>0.05). However, patients with high levels of p53 and LC3A co-expression had poor clinical prognoses (P=0.027). Thus, p53 and LC3A co-expression is an independent prognostic marker for patients with ESCC.

View Figures

View References

1	Ke L: Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970–90. Int J Cancer. 102:271–274. 2002.PubMed/NCBI
2	Yoon HH, Khan M, Shi Q, et al: The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 85:1080–1089. 2010. View Article : Google Scholar : PubMed/NCBI
3	Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar
4	Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM and Reynolds JV: Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus. 16:17–23. 2003.
5	Ito Y, Takeda T, Sasaki Y, et al: Bcl-2 expression in cholangiocellular carcinoma is inversely correlated with biologically aggressive phenotypes. Oncology. 59:63–67. 2000. View Article : Google Scholar : PubMed/NCBI
6	Kunnumakkara AB, Diagaradjane P, Guha S, et al: Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. 14:2128–2136. 2008. View Article : Google Scholar
7	Morselli E, Shen S, Ruckenstuhl C, et al: p53 inhibits autophagy by interacting with the human ortholog of yeast Atg17, RB1CC1/FIP200. Cell Cycle. 10:2763–2769. 2011. View Article : Google Scholar : PubMed/NCBI
8	Levine B: Cell biology: autophagy and cancer. Nature. 446:745–747. 2007. View Article : Google Scholar : PubMed/NCBI
9	Rouschop KM, Ramaekers CH, Schaaf MB, et al: Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiother Oncol. 92:411–416. 2009. View Article : Google Scholar : PubMed/NCBI
10	Mathew R, Karp CM, Beaudoin B, et al: Autophagy suppresses tumorigenesis through elimination of p62. Cell. 137:1062–1075. 2009. View Article : Google Scholar : PubMed/NCBI
11	Tey SK and Khanna R: Autophagy mediates transporter associated with antigen processing-independent presentation of viral epitopes through MHC class I pathway. Blood. 120:994–1004. 2012. View Article : Google Scholar
12	Hu YL, Jahangiri A, Delay M, et al: Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res. 72:4294–4299. 2012. View Article : Google Scholar : PubMed/NCBI
13	He H, Dang Y, Dai F, et al: Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. J Biol Chem. 278:29278–29287. 2003. View Article : Google Scholar : PubMed/NCBI
14	Sivridis E, Koukourakis MI, Mendrinos SE, Touloupidis S and Giatromanolaki A: Patterns of autophagy in urothelial cell carcinomas-the significance of ‘stone-like’ structures (SLS) in transurethral resection biopsies. Urol Oncol. Jan 24–2012.(Epub ahead of print).
15	Karpathiou G, Sivridis E, Koukourakis MI, et al: Light-chain 3A autophagic activity and prognostic significance in non-small cell lung carcinomas. Chest. 140:127–134. 2011. View Article : Google Scholar : PubMed/NCBI
16	Sivridis E, Giatromanolaki A, Liberis V and Koukourakis MI: Autophagy in endometrial carcinomas and prognostic relevance of ‘stone-like’ structures (SLS): what is destined for the atypical endometrial hyperplasia? Autophagy. 7:74–82. 2011.PubMed/NCBI
17	Giatromanolaki A, Koukourakis MI, Harris AL, Polychronidis A, Gatter KC and Sivridis E: Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. J Clin Pathol. 63:867–872. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sivridis E, Giatromanolaki A, Karpathiou G, Karpouzis A, Kouskoukis C and Koukourakis MI: LC3A-positive ‘stone-like’ structures in cutaneous squamous cell carcinomas. Am J Dermatopathol. 33:285–290. 2011.
19	Hofseth LJ, Hussain SP and Harris CC: p53: 25 years after its discovery. Trends Pharmacol Sci. 25:177–181. 2004.
20	Sobin LH and Wittekind CH; International Union against Cancer. TNM Classification of Malignant Tumors. 6th ed. Wiley-Liss; New York: pp. 52–56. 2002
21	Ishida M, Morita M, Saeki H, et al: Expression of p53 and p21 and the clinical response for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the esophagus. Anticancer Res. 27:3501–3506. 2007.PubMed/NCBI
22	Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
23	Han U, Can OI, Han S, Kayhan B and Onal BU: Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma? Dis Esophagus. 20:379–385. 2007. View Article : Google Scholar : PubMed/NCBI
24	Heeren PA, Kloppenberg FW, Hollema H, Mulder NH, Nap RE and Plukker JT: Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res. 24:2579–2583. 2004.PubMed/NCBI
25	Taghavi N, Biramijamal F, Sotoudeh M, et al: Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol. 16:4958–4967. 2010. View Article : Google Scholar : PubMed/NCBI
26	Ressiot E, Dahan L, Liprandi A, et al: Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol. 32:567–577. 2008. View Article : Google Scholar : PubMed/NCBI
27	Fujii S, Mitsunaga S, Yamazaki M, et al: Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 99:1813–1819. 2008.PubMed/NCBI
28	Sivridis E, Koukourakis MI, Mendrinos SE, et al: Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. Melanoma Res. 21:188–195. 2011. View Article : Google Scholar : PubMed/NCBI
29	Lee IH, Kawai Y, Fergusson MM, et al: Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science. 336:225–228. 2012. View Article : Google Scholar : PubMed/NCBI
30	Budanov AV and Karin M: p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 134:451–460. 2008. View Article : Google Scholar : PubMed/NCBI
31	Xia HG, Zhang L, Chen G, et al: Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy. 6:61–66. 2010. View Article : Google Scholar : PubMed/NCBI
32	Moretti L, Cha YI, Niermann KJ and Lu B: Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress? Cell Cycle. 6:793–798. 2007. View Article : Google Scholar : PubMed/NCBI